Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cleveland Clinic
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Infuseon Therapeutics, Inc.